Abstract |
Menarini Richerche is developing nepadutant, an NK2 antagonist, for the potential treatment of asthma and irritable bowel syndrome. The compound is in phase IIa trials in Belgium and Sweden for both these indications [359518].
|
Authors | A Ahluwalia |
Journal | Current opinion in investigational drugs (London, England : 2000)
(Curr Opin Investig Drugs)
Vol. 2
Issue 7
Pg. 919-22
(Jul 2001)
ISSN: 1472-4472 [Print] England |
PMID | 11757791
(Publication Type: Journal Article, Review)
|
Chemical References |
- Bronchodilator Agents
- MEN 11420
- Peptides, Cyclic
- Receptors, Neurokinin-2
- Neurokinin A
|
Topics |
- Animals
- Asthma
(drug therapy)
- Bronchodilator Agents
(chemical synthesis, pharmacology, therapeutic use)
- Colonic Diseases, Functional
(drug therapy)
- Humans
- Neurokinin A
(metabolism, physiology)
- Peptides, Cyclic
(chemical synthesis, pharmacology, therapeutic use)
- Receptors, Neurokinin-2
(antagonists & inhibitors)
- Structure-Activity Relationship
|